Cogent Biosciences vs Mirum Pharmaceuticals

Cogent Biosciences (COGT), health care, and Mirum Pharmaceuticals (MIRM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Mirum Pharmaceuticals is worth $6B on the stock market and Cogent Biosciences $4.8B: Mirum Pharmaceuticals is valued at 24% more. Over the past year Cogent Biosciences's share price has moved -17.8% and Mirum Pharmaceuticals's +26.9%.

Key facts

Cogent Biosciences market value
$4.8B
Mirum Pharmaceuticals market value
$6B
Mirum Pharmaceuticals revenue
$521.3MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Cogent Biosciences vs Mirum Pharmaceuticals: every measure side by side
Measure Cogent Biosciences Mirum Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$4.8Blower$6Bhigher
Revenue—$521.3M
Earnings-$328.9Mlower-$23.4Mhigher
Employees258lower470higher
Total assets$937.6Mhigher$842.8Mlower
Valuation
P/E——
P/S—11.5
P/B10.7—
Dividend yield0.00%0.00%
Profitability
Operating margin—-4.25%
Balance sheet
Net assets$636.4Mhigher$314.7Mlower
Total liabilities$301.2Mlower$528.1Mhigher
Total debt$222.9M—
Cash on hand$312Mhigher$296.7Mlower
Price change
Today+1.49%higher+0.40%lower
1 year-17.8%lower+26.9%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Cogent Biosciences only (1)

Mirum Pharmaceuticals only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns COGT · Who owns MIRM

Further comparisons

Learn

Questions and answers

Which is bigger, Cogent Biosciences or Mirum Pharmaceuticals?

By market value, Mirum Pharmaceuticals is the larger: $6B against $4.8B for Cogent Biosciences.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Cogent Biosciences and Mirum Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Cogent Biosciences and 3 hold Mirum Pharmaceuticals.

Cite this page

Funkfolio, “Cogent Biosciences vs Mirum Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/cogt-vs-mirm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.